The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction
Abstract Finerenone is a novel non-steroidal mineralocorticoid receptor (MR) antagonist (MRA) with high binding affinity, high MR selectivity and a short plasma half-life. In two major endpoint-driven clinical trials in patients with chronic kidney disease and type 2 diabetes mellitus (FIDELIO-DKD a...
Αποθηκεύτηκε σε:
| Κύριοι συγγραφείς: | , |
|---|---|
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
BMC
2023-06-01
|
| Σειρά: | Cardiovascular Diabetology |
| Θέματα: | |
| Διαθέσιμο Online: | https://doi.org/10.1186/s12933-023-01899-0 |
| Ετικέτες: |
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|